ALT
Altimmune, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +11.1% ·
share flow +5.6% ·
net new positions +10.0%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 82 | +6 | 85.94M | $261.24M | +14 | −8 |
| Q1 2026 | 78 | 0 | 58.31M | $179.46M | +8 | −8 |
| Q4 2025 | 77 | +2 | 45.71M | $165.02M | +3 | −1 |
| Q3 2025 | 15 | 0 | 25.85M | $97.47M | +1 | −1 |
| Q2 2025 | 12 | +1 | 18.03M | $69.77M | +1 | — |
| Q1 2025 | 8 | -2 | 8.83M | $44.16M | — | −2 |
| Q4 2024 | 10 | +1 | 7.53M | $54.26M | +1 | — |
| Q3 2024 | 8 | 0 | 3.66M | $22.46M | — | — |
| Q2 2024 | 8 | — | 3.17M | $21.05M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 3.47M | — | $25.02M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.66M | -0.6% | $11.96M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.66M | -0.6% | $11.96M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 675.04K | +57.9% | $4.87M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 675.04K | +57.9% | $4.87M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Two Sigma Investments ✦ | 605.30K | +33.2% | $4.36M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 459.83K | -39.3% | $3.32M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | Millennium Management ✦ | 345.64K | +231.9% | $2.49M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | Wellington Management ✦ | 205.23K | +4.1% | $1.48M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Wellington Management ✦ | 205.23K | +4.1% | $1.48M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | Marshall Wace ✦ | 65.52K | New | $472,378 | 0.0% | New | 1 | SEC ↗ |
| 12 | Marshall Wace ✦ | 65.52K | New | $472,378 | 0.0% | New | 1 | SEC ↗ |
| 13 | Marshall Wace ✦ | 65.52K | New | $472,378 | 0.0% | New | 1 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 28.15K | +17.3% | $203,000 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 12.58K | -47.3% | $90,680 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 12.58K | -47.3% | $90,680 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $472,378 | 0.0% |
| Marshall Wace | $472,378 | 0.0% |
| Marshall Wace | $472,378 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 170 holders, 69.15M shares, $212.24M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer, Director · President and CEO · 15.00K sh @ 2.95 · $44,250
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology